Receptor News and Research

RSS

Advances in stem cell research

Scientists at The University of Texas Health Science Center at Houston are on the forefront of stem cell research, developing novel therapies designed to generate heart cells, repair traumatic lung injuries, grow new bone and stanch the spread of cancer cells.

8 Mar 2009

Stem cells could halt osteoporosis, promote bone growth

While interferon gamma sounds like an outer space weapon, it's actually a hormone produced by our own bodies, and it holds great promise to repair bones affected by osteoporosis.

4 Mar 2009

Opioid antagonists help pain management

Achieving effective, durable, and safe pain relief, especially in patients with chronic and/or severe pain conditions, can be difficult.

3 Mar 2009

Trial looks at telmisartan in treating non-alcoholic steatohepatitis

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are well-recognized causes of progressive liver disease leading to cirrhosis and hepatocellular carcinoma.

3 Mar 2009

Bionovo announces publication of positive trial results for Menerba

Bionovo, Inc. has announced the online publication of a peer-reviewed article in the journal, Menopause, reporting Menerba (formerly MF101) is well tolerated, safe and effective for the treatment of vasomotor symptoms (hot flashes and night sweats) associated with menopause.

3 Mar 2009

Aerovance starts trial of Aerovant for uncontrolled asthma

Aerovance Inc. has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate Aerovance's Phase IIb clinical trial, AeroTrial(TM), of inhaled dry powder Aerovant in patients with uncontrolled asthma.

3 Mar 2009

Discovery provides better understanding of craniosynostosis

Craniosynostosis develops in the womb and affects one in every 2500 live births. Bones in the skulls and face of sufferers fuse together prematurely causing a range of distressing developmental problems.

2 Mar 2009

The obesity paradox

It's called the obesity paradox. Although obese people are more apt to suffer from inflammatory diseases, such as diabetes, heart disease, and stroke, they are also more likely to survive a major attack caused by one of those conditions.

26 Feb 2009

Novel approach to gene hunting uncovers possible new targets for Crohn's disease drugs

Discovering the different genes that contribute to a complex disease is like searching in the proverbial haystack for an unknown number of needles--some much smaller than others, often blending into the background, and many of them widely separated from each other.

26 Feb 2009

Eavesdropping on cellular communication

Scientists have discovered the secrets of a sophisticated molecule that plays a role in many aspects of human health from fertility to blood pressure; digestion to mental health.

25 Feb 2009

Medivation announces new positive efficacy data from trial of MDV3100 in Castration-resistant prostate cancer

Medivation, Inc. has announced the presentation of new efficacy and safety data from an ongoing Phase 1-2 clinical trial of the Company's novel androgen receptor antagonist MDV3100 in castration-resistant prostate cancer (CRPC) patients.

25 Feb 2009

Aton Pharma acquires Timoptic product line from Merck & Co

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has acquired the U.S. marketing rights to the Timoptic product line from Merck & Co., Inc. Timoptic (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

25 Feb 2009

Protein found linking stress and depression

Stress, the ever-present threat to health and happy living, is tough on the brain. If the strain goes on too long, it can lead to debilitating psychological problems.

25 Feb 2009

Chili Peppers continue to help unravel mechanism of pain sensation

Capsaicin, the active ingredient in chili peppers, generally is viewed as an irritant that produces a burning sensation when applied to a sensitive area of the body, such as the cornea.

25 Feb 2009

Implicit licenses clinical stage antibody program from Lilly

Implicit Bioscience Ltd has announced the acquisition of the clinical-stage monoclonal antibody IC14 from Eli Lilly and Company. Implicit has paid an undisclosed consideration combining cash and stock to Lilly. Lilly will also receive a royalty on future IC14 sales.

25 Feb 2009

Brain protein may be a target for fast-acting antidepressants

It takes weeks or months for the effect of most antidepressants to kick in, time that can feel like an eternity to those who need the drugs the most. But new research suggests that a protein called p11, previously shown to play a role in a person's susceptibility to depression, activates a serotonin receptor in the brain known for producing

25 Feb 2009

Researchers identify molecule that helps the sleep-deprived to mentally rebound

Sleep experts know that the mental clarity lost because of a few sleepless nights can often be restored with a good night's rest. Now, UT Southwestern Medical Center researchers have identified a key molecular mechanism that regulates the brain's ability to mentally compensate for sleep deprivation.

25 Feb 2009

Valdoxan granted marketing authorisation for the treatment of major depressive episodes in Europe

The European Commission has granted marketing authorisation for Servier's Valdoxan/Thymanax (agomelatine), the first melatonergic antidepressant for the treatment of adult patients with major depressive episodes.

24 Feb 2009

Researchers identify key molecular mechanism that regulates brain's ability to mentally compensate for sleep deprivation

Sleep experts know that the mental clarity lost because of a few sleepless nights can often be restored with a good night's rest.

24 Feb 2009

Xencor and CSL Limited establish antibody optimization collaboration

Xencor, Inc., an antibody discovery and development company, announced today that it has entered into an antibody optimization collaboration with CSL, Ltd. The collaboration will provide CSL with access to Xencor's XmAb technology platform to enhance the ADCC effector function of its therapeutic antibodies.

23 Feb 2009